REZOLUTE INC. - COMMON STOCK (NV)

Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

04 May 2021 07:00:01 By Nasdaq GlobeNewswire

Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners

19 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021

22 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences in March

02 Mar 2021 16:16:51 By Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2021 Financial Results

10 Feb 2021 15:05:00 By Nasdaq GlobeNewswire

Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

12 Jan 2021 07:30:00 By Nasdaq GlobeNewswire